ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance

Affiliation auteurs!!!! Error affiliation !!!!
TitreANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance
Type de publicationJournal Article
Year of Publication2020
AuteursTerrier B, Charles P, Aumaitre O, Belot A, Bonnotte B, Crabol Y, Durel C-A, Ebbo M, Jourde-Chiche N, Lega J-C, Puechal X, Pugnet G, Quemeneur T, Ribi C, Samson M, Vandergheynst F, Guillevin L, Grp FVasculitis
JournalPRESSE MEDICALE
Volume49
Pagination104031
Date PublishedOCT
Type of ArticleReview
ISSN0755-4982
Mots-clésBiotherapies, Immunoglobulins, Immunosuppressants, Mepolizumab, Plasma exchanges, Rituximab, vasculitis
Résumé

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience. (C) 2020 Elsevier Masson SAS. All rights reserved.
DOI10.1016/j.lpm.2020.104031